US 2018/0021403 A1 · Combination Therapy

Abstract

The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.

Claims21

Dependent claims

A combination comprising:

(i) a proteasome inhibitor and pharmaceutically acceptable salts thereof;
and (ii) a cyclic peptide, wherein the cyclic peptide comprises an exposed Arg-Gly-Asp (RGD) moiety;
wherein the ratio of proteasome inhibitor to cyclic peptide component ranges from 1:5000 to 10:1 w/w.

Dependencies are inferred from the claim text.

Facts

Application

15/523,188Filed 27 Oct 2015

Priority

GB 1419311.430 Oct 2014

Published

25 Jan 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 38/12
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins…
A61K 31/4015
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: having oxo groups…
A61K 31/407
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with other…
A61K 31/69
Medicinal preparations containing organic active ingredients: boron compounds

Combination Therapy

Life of this patent

Combination Therapy

Life of this patent

Abstract

Claims21